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We are testing a number of expression plasmids (pDNA) encoding SARS-CoV antigens to support potential development of a pDNA vaccine against this emerging pathogen. Our constructs are all derived from SARS-CoV Urbani and include the complete coding sequence for the nucleocapsid antigen, the soluble (extracellular) portion of the spike antigen, and two subdomains of the spike antigen termed S1 and S2. The codons used in these constructs were optimized for expression in human cells. These pDNAs were assayed for expression both *in vitro* and *in vivo*. Western blots of *in vitro* transfected cell lysates and culture supernatants were probed with a rabbit polyclonal antibody specific to either spike or nucleocapsid peptides. These assays indicate that the spike antigen is efficiently released from cells in culture whereas the nucleocapsid antigen remains predominately intracellular. All four pDNAs were formulated in either cationic lipid or poloxamer and injected into mouse (50 mg) or rabbit (1 mg) muscle tissue (i.e. 3X @ two week intervals). Sera from pDNA-vaccinated animals will be tested for virus neutralization in *vitro*. The use of one or more of these pDNA vaccines will be further evaluated for their immunogenicity and safety in animal models.
